

The role of skin specific genes in skin cancer

Group 3: Binnur Özay, Christofer Richard, Denisa Neacsu, Pinar Cavus

Supervisor: Dr. Maria Dinkelacker

Tutor: Nils Mechtel

Molecular Biotechnology B.Sc, Ruprecht Karls University of Heidelberg, SS21

Dinkelacker, 2007. A database of genes that are expressed in a tissue-restricted manner to analyse promiscuous gene expression in medullary thymic epithelial cells. Diplomarbeit, Albert-Ludwigs-Universitaet, Freiburg, Germany.

Dinkelacker, 2019. Chromosomal clustering of tissue restricted antigens, Dissertation, University Heidelberg, Germany.



Background


Why do we want to focus on TRAs?

melanoma -> one of the most common type of cancer in humans, also most **metastatic** among all cancers!

tissue restricted antigens (TRAs)

- upregulated in cancer cells for unknown reasons
- potential drug targets

Pie Chart skin specific TRAs





What are we working with?

Data Description

Human melanoma cell line with a BRAF-V600D mutation

all microarrays proved to be of good quality.

treated with:

- trametinib: MEK-Inhibitor —————> 3h - 24h
- ERK1/2-Inhibitor —————> 3h - 24h
- doxycycline-shERK1 —————> 3d - 7d



Objectives


Identifying **upregulated skin specific TRAs in skin cancer**, and investigating them to see if they are possible drug targets.

After identifying upregulated genes:

- are our identified genes **related to sun exposure**?
- are there any interesting **groups**?
- are there any **non skin-specific TRAs** that are upregulated in skin cancer?
- do the **efficacy of the drugs** vary?
- can we **predict the expression** of these genes by using other genes (potential targets)?

Highly expressed genes

Highly expressed skin genes in melanoma



ANXA2: cancer biomarker

GPNMB: pro-metastatic protein

both responsible for the biogenesis
of **melanosomes!**

melanosomes in melanocytes

melanoma develops from
melanocytes



Differential Gene Expression Analysis


Upregulated skin specific TRAs

no data available from cells without treatment → start point for differential expression analysis: three hours and three days

- **log2 fold change:** within the chips with the same treatment time-frame
- **t-test:** significance of ten genes from each chip with the highest log-fold change ($p < 0.05$)
- **limma analysis:** same genes were found, confirmed


Heatmap of upregulated genes

Expression of upregulated genes




Significantly upregulated skin specific TRAs

Upregulated genes in treatment with ERK1/2 inhibitor



Upregulated genes in treatment with Trametinib





Differential gene expression analysis

Downregulated skin specific TRAs


The existence of significantly downregulated genes indicates:

- these genes were probably **inducing tumors before the treatment**
- the **treatment is successfully working.**


Methods: log2 fold change, t-test

Significantly downregulated skin specific TRAs

Downregulated genes in treatment with ERK1/2 inhibitor



Downregulated genes in treatment with Trametinib




Gatekeeper of G2-M cell cycle ---|
 proliferation

Importance of TYRP1 (and MITF!)

- Trametinib & ERK1/2 inhibitor → upregulation
Dox-shERK → downregulation
- **microphthalmia-associated transcription factor (MITF):**
 - natural function : melanosome development
 - melanoma : master regulator, crucial for the survival of the melanoma cell


BRAF & MEK inhibitors (trametinib) ² → MITF ¹ → TYRP1 & melanoma proliferation

Downregulated genes in treatment with Sherk



Clustering of the upregulated skin-specific TRAs

Visualization via k-means



MITF and EMT in Melanoma

epithelial-mesenchymal transition (EMT): transition from proliferative epithelial cells to invasive cells

expectation:

MITF ↑

- MITF related genes: TPRM1, PPFBIBP2 ↑
- EMT-like process ✗ : TGFBI, ARHGEF5 ↓
- proliferative stage


MITF ↓

- MITF related genes: TPRM1, PPFBIBP2 ↓
- EMT-like process ✓ : TGFBI, ARHGEF5 ↑
- invasive stage


our data:

- TGFBI, ARHGEF5 ↑
- TPRM1, PPFBIBP2 ↑

EMT related genes



Why?



Hypothesis: **high MITF expression** has a responsibility over **proliferation AND metastasis in melanoma**.



Expression with and without the sun

Genes upregulated under sun exposure

Wilcoxon signed rank test and clustering: significant difference between expressions

ARHGEF5, TGFBI, DAPL1: upregulated by MITF


→ **conformation**: triggering effects of MITF and sun exposure on melanoma

→ upregulation by MITF under sun exposure?

ETV7: usually downregulated in melanoma

→ upregulated under trametinib under the sun

→ **suspicion**: natural response plus treatment, attacking the tumor microenvironment






Non-skin specific TRAs

Venn diagram


non skin-specific TRAs that are **upregulated** in skin cancer to be used as potential drug targets.

Potential drug targets



Principal Component Analysis (PCA)

PC1 and PC2 represent **97.7% of all the variance** of the melanoma dataset.



5 genes with most contribution from each PCs:

- from PC1: ANXA2, DCT, NDRG1, TYRP1, PTPRZ1
- from PC2: DSP, GJA1, PPP1R14C, TGFB1, UCN2




Multiple linear regression

Any significant dependencies between the PC genes and the upregulated genes?

- Residuals meet the conditions!

Correlation:


- Upregulated gene representatives: MPZL3, ARHGEF5 (for all the other genes)
- PC gene representatives: GJA1, DSP, ANXA2






Multiple linear regression

Multiple linear regression of MPZL3




Multiple linear regression of ARHGEF5





Simple linear regression

Independent variables with the highest impact; ANXA2



high correlation between upregulated genes:

- almost all upregulated genes predicted together
- better diagnosis
- when biological connection: pc genes also drug targets



Objectives

Upregulated skin specific TRAs in skin cancer identified ✓

Are our identified genes **related to sun exposure**? ✓

- Yes! Four genes that are upregulated are also sun exposed.

Are there any **non skin-specific TRAs** that are upregulated in skin cancer? ✓

- No!

Can we **predict the expression** of the upregulated genes by using other genes (potential targets)? ✓

- Yes! Most of the identified upregulated genes can be predicted by ANXA2, DSP, GJA1.

Do the **efficacy of the drugs** vary? ✓

- Yes! The treatments showed varying effects on different genes. The effect of the MAPK pathway inhibitors on melanoma are questionable, combination therapy may be needed.

Are there any interesting **groups**? ✓

- Yes! MITF related genes have an important role in melanoma and are good drug targets.